CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,696,522 | +52.0% | 5,747,587 | +11.6% | 0.00% | +100.0% |
| Q2 2023 | $56,380,236 | +45.3% | 5,148,880 | +15.7% | 0.00% | 0.0% |
| Q1 2023 | $38,800,582 | +68.4% | 4,449,608 | +21.1% | 0.00% | 0.0% |
| Q4 2022 | $23,044,118 | +79.6% | 3,675,298 | +0.3% | 0.00% | – |
| Q3 2022 | $12,828,000 | +22.3% | 3,665,062 | +3.0% | 0.00% | – |
| Q2 2022 | $10,493,000 | -12.2% | 3,557,042 | -7.4% | 0.00% | – |
| Q1 2022 | $11,950,000 | -6.7% | 3,842,376 | +1.4% | 0.00% | – |
| Q4 2021 | $12,805,000 | +4.9% | 3,788,457 | +13.2% | 0.00% | – |
| Q3 2021 | $12,211,000 | -15.8% | 3,345,308 | +0.6% | 0.00% | – |
| Q2 2021 | $14,505,000 | -13.5% | 3,326,782 | -10.0% | 0.00% | – |
| Q1 2021 | $16,773,000 | -14.7% | 3,694,418 | +7.8% | 0.00% | -100.0% |
| Q4 2020 | $19,670,000 | -19.5% | 3,427,011 | +1.6% | 0.00% | 0.0% |
| Q3 2020 | $24,422,000 | +107.0% | 3,373,119 | -0.2% | 0.00% | – |
| Q2 2020 | $11,798,000 | +116.0% | 3,380,750 | -8.4% | 0.00% | – |
| Q1 2020 | $5,462,000 | -24.5% | 3,689,840 | -0.0% | 0.00% | – |
| Q4 2019 | $7,235,000 | -61.6% | 3,691,325 | +0.4% | 0.00% | -100.0% |
| Q3 2019 | $18,828,000 | -26.1% | 3,677,394 | +3.3% | 0.00% | 0.0% |
| Q2 2019 | $25,488,000 | -42.4% | 3,559,875 | +6.8% | 0.00% | -50.0% |
| Q1 2019 | $44,262,000 | +91.6% | 3,332,969 | +13.5% | 0.00% | +100.0% |
| Q4 2018 | $23,101,000 | -25.2% | 2,935,490 | +5.2% | 0.00% | 0.0% |
| Q3 2018 | $30,903,000 | -14.1% | 2,789,188 | +4.1% | 0.00% | -50.0% |
| Q2 2018 | $35,955,000 | +9.0% | 2,679,199 | +5.5% | 0.00% | +100.0% |
| Q1 2018 | $32,981,000 | +101.5% | 2,538,914 | +42.7% | 0.00% | 0.0% |
| Q4 2017 | $16,370,000 | +31.8% | 1,779,307 | +15.4% | 0.00% | 0.0% |
| Q3 2017 | $12,422,000 | +117.5% | 1,541,202 | +55.4% | 0.00% | – |
| Q2 2017 | $5,712,000 | +61.7% | 991,633 | +20.7% | 0.00% | – |
| Q1 2017 | $3,532,000 | +286.9% | 821,507 | +55.7% | 0.00% | – |
| Q4 2016 | $913,000 | -23.4% | 527,684 | -14.2% | 0.00% | – |
| Q3 2016 | $1,192,000 | +11.9% | 614,705 | +0.4% | 0.00% | – |
| Q2 2016 | $1,065,000 | +43.5% | 612,249 | +11.4% | 0.00% | – |
| Q1 2016 | $742,000 | -12.0% | 549,353 | +10.2% | 0.00% | – |
| Q4 2015 | $843,000 | -99.5% | 498,726 | -90.5% | 0.00% | -100.0% |
| Q3 2015 | $157,663,000 | +17535.7% | 5,272,017 | +1486.5% | 0.01% | – |
| Q2 2015 | $894,000 | -59.4% | 332,307 | +4.5% | 0.00% | – |
| Q1 2015 | $2,201,000 | -21.7% | 318,047 | +11.3% | 0.00% | – |
| Q4 2014 | $2,810,000 | +45.4% | 285,847 | +1.2% | 0.00% | – |
| Q3 2014 | $1,932,000 | – | 282,447 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |